HUE056006T2 - Kombináció Parkinson-kór kezelésére - Google Patents

Kombináció Parkinson-kór kezelésére

Info

Publication number
HUE056006T2
HUE056006T2 HUE14718177A HUE14718177A HUE056006T2 HU E056006 T2 HUE056006 T2 HU E056006T2 HU E14718177 A HUE14718177 A HU E14718177A HU E14718177 A HUE14718177 A HU E14718177A HU E056006 T2 HUE056006 T2 HU E056006T2
Authority
HU
Hungary
Prior art keywords
parkinson
disease
treatment
combination
Prior art date
Application number
HUE14718177A
Other languages
English (en)
Hungarian (hu)
Inventor
Oron Yacoby-Zeevi
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50513395&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE056006(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of HUE056006T2 publication Critical patent/HUE056006T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE14718177A 2013-03-13 2014-03-13 Kombináció Parkinson-kór kezelésére HUE056006T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779357P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
HUE056006T2 true HUE056006T2 (hu) 2022-01-28

Family

ID=50513395

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14718177A HUE056006T2 (hu) 2013-03-13 2014-03-13 Kombináció Parkinson-kór kezelésére

Country Status (21)

Country Link
US (4) US20160022573A1 (https=)
EP (2) EP2968218B1 (https=)
JP (2) JP6472391B2 (https=)
KR (1) KR102209353B1 (https=)
CN (2) CN105209029A (https=)
AU (1) AU2014229127B2 (https=)
BR (1) BR112015022390A8 (https=)
CA (1) CA2904838C (https=)
CL (1) CL2015002641A1 (https=)
DK (1) DK2968218T3 (https=)
ES (1) ES2889626T3 (https=)
HR (1) HRP20211442T1 (https=)
HU (1) HUE056006T2 (https=)
IL (1) IL266648B (https=)
MX (1) MX365206B (https=)
PL (1) PL2968218T3 (https=)
PT (1) PT2968218T (https=)
RU (2) RU2677278C2 (https=)
SG (2) SG10201911731YA (https=)
WO (1) WO2014141261A1 (https=)
ZA (1) ZA201507621B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2432454T3 (pl) 2009-05-19 2017-10-31 Neuroderm Ltd Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
PT2640358T (pt) 2010-11-15 2018-02-23 Neuroderm Ltd Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
TR201808178T4 (tr) 2010-11-15 2018-07-23 Neuroderm Ltd Aktif ajanların transdermal dağıtımı için bileşimler.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3116475T3 (da) * 2014-03-13 2020-12-07 Neuroderm Ltd Dopa-decarboxylasehæmmersammensætninger
JP6622310B2 (ja) 2014-09-04 2019-12-18 ロブソル・ファーマシューティカルズ・アクチボラグLobsor Pharmaceuticals Aktiebolag レボドパ、ドーパミン脱炭酸酵素阻害薬およびcomt阻害薬を含む医薬組成物ならびにその投与方法
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
CA3065990A1 (en) * 2017-06-05 2018-12-13 Dizlin Pharmaceuticals Ab Levodopa infusion solution
WO2019097120A1 (en) * 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
US11806326B2 (en) 2018-01-29 2023-11-07 Jonathan Sackner-Bernstein Methods for dopamine modulation in human neurologic diseases
BR112020017422A2 (pt) * 2018-03-29 2020-12-22 Avion Pharmaceuticals , Llc Composição de dose fracionada de levodopa e uso
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2023282900A1 (en) * 2021-07-08 2023-01-12 Morehouse School Of Medicine Method and system of diagnosing and treating neurodegenerative disease and seizures
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
PL1896006T3 (pl) * 2005-06-08 2010-03-31 Orion Corp Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
PL2432454T3 (pl) * 2009-05-19 2017-10-31 Neuroderm Ltd Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
PT2640358T (pt) 2010-11-15 2018-02-23 Neuroderm Ltd Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos

Also Published As

Publication number Publication date
RU2677278C2 (ru) 2019-01-16
CN105209029A (zh) 2015-12-30
US20160022573A1 (en) 2016-01-28
JP6625773B2 (ja) 2019-12-25
WO2014141261A1 (en) 2014-09-18
AU2014229127B2 (en) 2018-04-05
KR102209353B1 (ko) 2021-01-29
BR112015022390A8 (pt) 2019-11-26
SG11201507538UA (en) 2015-10-29
RU2018144700A (ru) 2019-02-18
BR112015022390A2 (pt) 2017-07-18
CL2015002641A1 (es) 2016-03-18
SG10201911731YA (en) 2020-02-27
CN110935026A (zh) 2020-03-31
MX2015012561A (es) 2016-06-28
PT2968218T (pt) 2021-09-24
CA2904838C (en) 2021-03-16
US20210093560A1 (en) 2021-04-01
EP2968218B1 (en) 2021-07-07
JP6472391B2 (ja) 2019-02-20
JP2016512230A (ja) 2016-04-25
AU2014229127A1 (en) 2015-11-05
DK2968218T3 (da) 2021-09-20
ZA201507621B (en) 2019-04-24
EP2968218A1 (en) 2016-01-20
HRP20211442T1 (hr) 2022-02-04
IL266648A (en) 2019-07-31
US20230047847A1 (en) 2023-02-16
ES2889626T3 (es) 2022-01-12
CA2904838A1 (en) 2014-09-18
RU2015143112A (ru) 2017-04-20
KR20150131230A (ko) 2015-11-24
EP3892266A1 (en) 2021-10-13
IL266648B (en) 2020-08-31
MX365206B (es) 2019-05-27
JP2019070041A (ja) 2019-05-09
PL2968218T3 (pl) 2022-01-10
US20250177292A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
IL256166B (en) Compounds for use in treating neuromuscular disorders
IL243976A0 (en) kdm1a inhibitors for disease treatment
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
HUE059387T2 (hu) Parkinson-kór kezelése
IL243637A0 (en) PPAR-sparing compounds for the treatment of metabolic diseases
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
HUE045148T2 (hu) Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
SI2986325T1 (sl) Postopki zdravljenja motenj ciklusa sečnine
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
IL246148A0 (en) Treating brain disorders and biomarkers related thereto
IL261984B (en) Sultiame for the treatment of sleep apnea
LT3148588T (lt) N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui
HK40032828A (en) Methods for the treatment of mitochondrial disease
IL241482B (en) A method for treating Parkinson's disease
GB201306413D0 (en) The local treatment of ophthalmic diseases
GB201321628D0 (en) Treatment of disease
GB201310101D0 (en) Treatment of freidreich's ataxia
UA27795S (uk) Ковдра стьобана